Filing Flows › Comparisons › CVSI vs TRAW
CV Sciences vs Traws Pharma: CVSI and TRAW compared
CV Sciences is the larger company: $3.0M of revenue in its latest quarter (Q2 2026) against $2.7M for Traws Pharma (Q2 2025). Traws Pharma is growing faster (48× against -18% a year earlier). CV Sciences is more profitable, with an operating margin of -10.1% against -45.7%.
Where the money goes: CVSI and TRAW
CV Sciences (CVSI) · Q2 2026
CV Sciences, Q2 2026: revenue $3.0M (-18% year over year), operating margin -10.1%, net loss $775K, operating cash flow $20K. The chart follows the revenue to costs, profit and cash.
Traws Pharma (TRAW) · Q2 2025
Traws Pharma, Q2 2025: revenue $2.7M (48× year over year), operating margin -45.7%, net loss $915K, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
| CV Sciences (CVSI) | Traws Pharma (TRAW) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2025 |
| Revenue | $3.0M | $2.7M |
| Revenue growth, Y/Y | -18% | 48× |
| Operating margin | -10.1% | -45.7% |
| Net earnings | −$775K | −$915K |
| Net margin | -26.0% | -33.5% |
| Operating cash flow | $20K | −$6.0M |
| Free cash flow | $13K | — |
Questions
Which is bigger, CV Sciences or Traws Pharma?
CV Sciences is the larger company: $3.0M of revenue in its latest quarter (Q2 2026) against $2.7M for Traws Pharma (Q2 2025).
Is CV Sciences or Traws Pharma growing faster?
Traws Pharma is growing faster (48× against -18% a year earlier).
Which is more profitable, CV Sciences or Traws Pharma?
CV Sciences is more profitable, with an operating margin of -10.1% against -45.7%.
More: CV Sciences earnings · how CV Sciences makes money · Traws Pharma earnings · how Traws Pharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 14, 2025). Fiscal quarters can end on different dates. Not investment advice.